摘要
Necroptosis作为一种新发现的细胞死亡形式,在近些年成为研究的热点,Necroptosis是一种可被机体内多种信号转导因子高度调控的程序性坏死路径,属于细胞程序性死亡方式的一种特殊类型,被称为细胞程序性坏死或坏死性凋亡。该过程依赖于受体相互作用蛋白激酶RIP3及其底物混合谱系激酶结构域MLKL,且抑制剂Necrostain-1以及MLKL、PGAM5、RIP1、RIP3构成的坏死复合物是细胞程序性坏死的重要调节因子,坏死复合物的构成和磷酸化过程是Necroptosis的关键性步骤,也是Necroptosis发生的特异性标志。Necroptosis已经被认为是在病理环境下发生的细胞死亡和炎症的重要原因,与诸多疾病的病理和器质损伤有关,例如神经病变,病毒感染,心、脑、肾的缺血-再灌注损伤,恶性肿瘤和许多其它的病理情况等。该文将从Necroptosis的基本特点、机制以及与疾病的关系等多个方面进行概述。
Necroptosis is a newly found type of programmed cell death and has received widespread attention. Necroptosis can be regulated by many signal transduction factor, so it belongs to programmed necrosis, known as programmed cell necrosis or necrotic apoptosis. This process relies on the RIP3 and its substrate mixed lineage kinase domain MLKL, RIP1, RIP3, MLKL, PGAM5 and ne- crostain-1 are the key regulators of necroptosis. The formation and phosphorylation of RIP1-RIP3 complex is the key step, which is the specific marker of necroptosis. Necroptosis has been identified as an important cause of cell death and inflammation occurring in a pathological environment, and ralated tomany pathological and structural damage, such as neuropathy, viral infection, ischemic- reperfusion injury in the heart, brain, kidney, malignant tumors, and many other pathological conditions. This article will summarise characteristics of necroptosis, the mechanism and its relationship with disease and other aspects.
出处
《药物生物技术》
CAS
2017年第3期275-278,共4页
Pharmaceutical Biotechnology
基金
国家自然科学基金项目(No.81300969)
山东省自然科学基金(No.ZR2012HL27)
潍坊市科技局课题(No.20121373)